Medical Cannabis Safety, Standards and Regulation in Australia

Patient-safety information, not a product guide.

This resource focuses on risk, quality controls, monitoring and responsible use. It does not determine eligibility or promise treatment, prescribing, approval or access to any particular product.

Medicinal cannabis is often discussed as though it were a single medicine. In practice, products can differ in cannabinoid profile, route of administration, concentration, formulation and intended clinical use. That variation is one reason patient safety depends on more than obtaining a prescription. It also depends on product quality, clear instructions, monitoring, responsible storage and an assessment of whether the treatment is appropriate for the individual patient.

In Australia, most medicinal-cannabis products supplied through the Special Access Scheme or Authorised Prescriber pathways are unapproved therapeutic goods. The Therapeutic Goods Administration (TGA) notes that unapproved goods have not been evaluated by the TGA in the same way as products included in the Australian Register of Therapeutic Goods. That makes informed clinical decision-making, product standards and follow-up particularly important.

This page deliberately focuses on safety and standards. For the consultation and prescription pathway, see DocTel’s medical cannabis prescription assessment. For the broader telehealth service, visit Cannabis Telehealth Australia.

Every prescription medicine can produce effects beyond its intended benefit, and medicinal cannabis is no exception. What matters clinically is not memorising every possible effect, but knowing which ones are common and manageable, and which ones justify contacting the treating service sooner rather than waiting for a scheduled review.

Commonly reported effects with THC-containing products include drowsiness or sedation, dizziness, dry mouth, changes in appetite, and mild gastrointestinal effects such as nausea. Cognitive effects — slowed thinking, reduced concentration or short-term memory changes — are also common, particularly when a dose is first introduced or increased. CBD-dominant products can still cause fatigue, appetite change or gastrointestinal upset, even without the intoxicating effects associated with THC.

Individual response varies considerably. The same dose can affect two patients differently depending on their metabolism, other medicines, body weight, prior cannabis exposure and the specific formulation used. This is one reason a cautious starting approach and an early review are common features of a well-managed treatment plan, rather than a sign that something has gone wrong.

The distinction below is a general safety framework, not a diagnostic tool. It cannot replace the treating practitioner’s advice for an individual patient, and it does not remove the need to seek urgent care for a genuine emergency.

A product can look professional, use medical language and still require careful clinical and regulatory scrutiny. Patients should distinguish between branding claims and the controls that actually matter: lawful supply, appropriate prescribing, accurate labelling, reliable composition, pharmacy handling and instructions that match the prescribed formulation.

The Australian framework places responsibilities across sponsors, prescribers, pharmacists and patients. The details vary according to the product and access pathway, but the central principle is consistent: medicinal cannabis is handled as a therapeutic good, not as a recreational consumer product.

Patients should be cautious about services that blur the difference between a clinical consultation and a guaranteed product transaction. Patients who encounter informal terms such as ‘medical marijuana’, ‘medical weed’ or ‘MMJ’ can read DocTel’s medical-marijuana terminology guide; those labels do not change the safety standard applied in clinical care. A consultation should allow the practitioner to decide that medicinal cannabis is unsuitable, that more information is required, or that another treatment pathway is safer.

• Check that the product is supplied through a lawful Australian pathway.
• Use the exact dose and route directed by the treating practitioner.
• Do not assume two products with similar branding or cannabinoid labels are interchangeable.
• Ask the pharmacist or prescriber when storage, device use or administration instructions are unclear.

THC and CBD are the best-known cannabinoids, but the clinical relevance of a product cannot be reduced to a single number on a label. The ratio of cannabinoids, concentration, dose, formulation and timing can all change how a patient experiences a medicine. A person using an oral oil, for example, may experience a different onset and duration from a person using another prescribed dosage form.

THC-containing products can impair attention, reaction time, coordination and judgement. That has obvious implications for driving, operating machinery and safety-sensitive work — this is developed further below. CBD-dominant products can also have clinically relevant adverse effects or interactions. The absence of intoxication does not mean the absence of medical risk.

A treating practitioner cannot assess interaction risk from an incomplete picture. This is not a formality — it is one of the main reasons a safe prescribing decision is possible at all. The relevant list includes prescription medicines, over-the-counter products, vitamins and supplements, alcohol use and any other substances, even ones a patient might assume are unrelated to cannabis.

Some of the reasoning is general rather than product-specific: medicines that also cause sedation can compound drowsiness; medicines that affect the same liver metabolic pathways can change how much of a cannabinoid reaches the bloodstream; medicines that affect heart rate, blood pressure or bleeding risk may interact with cannabinoid effects on those same systems. The point of disclosure is not to frighten the patient with a checklist of chemistry — it is to let the practitioner reason about risk properly instead of guessing.

Patients should also mention any recent change in their other medicines at follow-up, not only at the first consultation. A medicine list that was accurate three months ago may no longer be accurate, and a new medicine started elsewhere — including one prescribed by another doctor — can change the risk picture for an existing cannabis prescription.

Safety does not end when a prescription is issued. Patients have an active role in monitoring treatment, following instructions and reporting changes. A clinician can only make a sound follow-up decision when they know what the patient actually used, what benefit was noticed, what adverse effects occurred and whether anything else changed.

Keep the medicine in its original labelled packaging and store it according to the pharmacy and manufacturer instructions. Do not share prescribed medicinal cannabis with another person. Do not change dose or route simply because a previous dose felt ineffective, and do not substitute another product without clinical or pharmacy advice.

Contact the treating service if adverse effects are persistent, unexpected or functionally significant. Seek urgent medical care for severe symptoms, acute confusion, severe breathing difficulty, chest pain, loss of consciousness, suicidal thoughts, a severe allergic reaction or another emergency concern.

• Record the dose, timing and effect if your practitioner has asked you to monitor treatment.
• Report new medicines or major changes in health before the next review.
• Ask about driving and work-safety implications rather than relying on how ‘normal’ you feel.
• Arrange follow-up when treatment effectiveness, tolerability or goals need reassessment.

Medicinal cannabis can intersect with mental-health care in complex ways. A practitioner may need to consider a history of psychosis, mania, severe anxiety, substance-use problems, suicidal thinking or other psychiatric risks before deciding whether a cannabis-based treatment is appropriate. The presence of a mental-health condition does not automatically determine the outcome, but it can materially change the risk assessment, and it is one reason a full and honest history matters more here than for many other medicines.

Patients with a personal or close family history of psychosis or bipolar disorder should expect this to be discussed openly rather than treated as disqualifying by default — it is a factor the practitioner needs to weigh, not an automatic exclusion. Similarly, a patient in active recovery from a substance-use disorder should expect the conversation to focus on how treatment could be monitored safely, not simply whether treatment is possible.

DocTel’s eligibility pathway is designed to identify important risk factors before booking, but it does not replace the practitioner’s clinical assessment. Patients who are unsure can begin with the Medicanna eligibility check.

THC-related impairment is genuinely difficult for a patient to judge from the inside. Tolerance can make a dose feel unremarkable while measurable effects on reaction time, attention and coordination are still present. This is a documented feature of THC generally, not a suggestion that any particular patient is being careless — it is exactly why the instruction from a treating practitioner should take priority over subjective judgement.

Two things are worth separating clearly. The first is the medical question: what a practitioner advises about driving or operating machinery based on the specific product, dose and the patient’s individual response, especially in the early weeks of treatment or after a dose change. The second is the legal question: drug-driving and impaired-driving road rules differ between Australian states and territories, and can apply to prescribed medicinal cannabis differently from the way they apply to other sedating prescription medicines. This page does not attempt to state the specific road rule in every jurisdiction, because those rules can change and a generic statement risks being wrong for a reader’s specific state or territory.

Patients should treat both questions as necessary, not optional: ask the treating practitioner what the clinical advice is for their situation, and separately confirm the current road rules that apply where they live and drive — through their state or territory transport or road-safety authority, or through their own legal adviser if the situation is unclear. Relying on how alert a person feels is not a substitute for either answer.

Storage is a practical safety issue, particularly in households with children, adolescents or pets. Medicinal cannabis should remain in its original pharmacy-labelled packaging and be stored according to the product instructions. Products should not be decanted into unlabelled containers or left where another person could mistake them for ordinary food, supplements or recreational cannabis.

Patients should also think about heat, light, humidity and device safety where relevant. If a product uses an administration device, use only the equipment recommended for that medicine and follow the pharmacist or manufacturer instructions. Damaged packaging, uncertain storage conditions or an unfamiliar appearance should prompt a pharmacy check before use.

Accidental ingestion or exposure can require urgent advice, particularly in children or pets. If this occurs, contact an appropriate emergency or poisons service and provide the product label and as much information as possible about the exposure.

A practical storage checklist:

• Original labelled packaging — never a repackaged or unlabelled container.
• Out of sight and out of reach of children, adolescents and pets.
• Away from heat, direct light and humidity, per the product instructions.
• Never shared with another person, even a household member with a similar condition.
• Checked against the label before use if packaging looks damaged or unfamiliar.

Safety monitoring is not limited to asking whether side effects occurred. The treatment should also be producing enough meaningful benefit to justify continuing. A medicine that is tolerated but does not improve the agreed clinical goal may still be an unsuccessful treatment.

Useful treatment goals are specific. Depending on the reason for care, a clinician may monitor sleep continuity, pain interference, daily function, frequency of a symptom, ability to work, or another measurable outcome. The goal should be realistic and linked to the patient’s reason for treatment rather than a vague expectation of feeling better.

A useful review typically covers four things: whether the treatment goal is being met, whether adverse effects are acceptable, whether the dose or product still fits the patient’s circumstances, and whether anything else has changed — new medicines, a new diagnosis, a change in mental health, or a change in driving or work duties. A practitioner may reduce a dose, change a formulation, pause treatment or stop it altogether if the balance of benefit and risk no longer supports continuing.

Patients can make follow-up more useful by recording both positive and negative effects between appointments rather than relying on memory at the review itself. It is reasonable to ask what outcome is being monitored, what would count as an inadequate response, and what should prompt an earlier review rather than waiting for the next scheduled one.

The TGA provides national pathways for access to unapproved therapeutic goods, including medicinal cannabis. State and territory requirements can also be relevant, particularly for controlled medicines and professional obligations. The prescriber remains responsible for practising within the law and within their professional scope.

For patients, the practical point is simple: a legitimate pathway should involve an Australian-registered health practitioner, a clinical assessment, a lawful prescription where appropriate and supply through an appropriate pharmacy pathway. A service should not represent regulatory access as automatic approval.

For detailed discussion of the Australian prescribing pathways themselves, read DocTel’s medical cannabis regulatory guide.

If you are considering medicinal cannabis, DocTel Medicanna provides a telehealth assessment pathway. The consultation is a clinical assessment and does not guarantee a prescription or a particular medicine.